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In western Europe during the spring, the largest proportion of fox populations are cubs and the 
key to successful rabies oral vaccination campaigns is cub vaccination. In this paper we report 
on studies of the serology of 93 fox (Vulpes vulpes) cubs born to unvaccinated and orally 
vaccinated captive vixens, some of which were orally vaccinated at 30 or at 90 days of age with 
the vaccinia recombinant vaccine (VR-G) that expresses the rabies virus glycoprotein. The 
duration of cub passively acquired antibody, the development of immune responses to oral 
vaccination at either 30 or 90 days of age, possible interference between passive and active 
immunity to such vaccination and resistance to a potentially lethal rabies challenge dose when 
five months old were measured. The study showed that rabies neutralising antibody can be 
passed to their cubs by vixens orally vaccinated with VR-G during pregnancy. Maternally derived 
antibody titres in cubs declined with time and disappeared by 45–75 days after birth. Thirty 
days old cubs serologically responded to oral vaccination. No interference between antibody of 
maternal origin and active immunity conferred by VR-G oral vaccination or between antibody of 
maternal origin and protection was observed. Thus, very young cub immunisation against rabies 
with VR-G per os is possible whatever the immune status of their mothers. Provided a vaccine-
bait suitable for such young cubs exists, oral vaccination at den entrances with VR-G is a 
feasibility. 
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The failure of other methods to halt the spread of rabies in the fox (Vulpes vulpes) populations 
of western Europe led to large scale field trials of fox oral vaccination. The first such trials were 
carried out in Switzerland in 1978, using a derivative (SADBern) of the Street Alabama Dufferin 
(SAD) attenuated strain of rabies virus conjoined to chicken-head baits [1]. In time, other 
derivatives of SAD such as SADB19 [2] and SAG1 and SAG2, the latter of which are escape mutants 
derived from monoclonal antibody neutralisation of the SADBern virus [3], were also used in 
trials, as was a vaccinia virus recombinant (VR-G) capable of expressing the immunising 
glycoprotein [4,5] of rabies virus. SAG2 and VR-G are now the only vaccines that fulfil all the 
World Health Organization (WHO) requirements for anti-rabies safety for numerous target and 
non-target wild animal species [6–9]. In parallel with the developments in vaccinal viruses, 
attention was focused on the development of baits and bait delivery systems such that, by the 
end of the twentieth century, vast numbers of vaccine-loaded machine-made baits had been 
dropped by fixed-wing aircraft or helicopters over vast areas of western Europe. 
Two related major hindrances to the complete eradication of rabies from western Europe were 
persistence of the disease in limited areas through lack of sustained vaccination campaigns 
and/or of sufficient bait density and resurgence of disease in areas apparently freed from 
infection. Both situations were exacerbated by natural increases in fox populations [10–12]. In 
spring, cubs are the largest group of a fox population; they are also the most difficult group to 
vaccinate. After spring campaigns, bait uptake ranges between 22 and 52% of cubs but reaches 
75% of adults. After autumn campaigns, bait uptake reaches 70–80% of both adult and young 
foxes [13]. According to Breitenmoser  et al. [14], the increase in the number of young 
unvaccinated foxes was the main reason of the persistence of rabies in the Swiss Jura. 
To combat this problem, some measures to improve the efficiency of fox oral vaccination, 
particularly of cubs, have already been tested in the field. For example, vaccination campaigns 
have been conducted during summer to reduce the period during which susceptible fox cubs are 
not immunised. Briefly, the results obtained from one such trial [15] showed no significant 
increase in the proportion of immunised young foxes. A trial to vaccinate cubs by vaccine bait 
distribution at the entrances to dens was also carried out and although successful it proved 
difficult to organise and was expensive [16,17]. 
In the field, most cubs in oral vaccination areas are offspring of immunised vixens. Thus, it is 
possible that maternally derived antibodies might interfere with the ability of the vaccine to 
provoke a lasting immunological response in the cubs. Such interference has been observed in 
other canids (reviewed in [18,19]). In this paper we record the results of our studies of the 
immunisation and resistance to a rabies challenge of fox cubs orally vaccinated with VR-G in 
both the presence and absence of maternal antibodies. We show that cubs can respond to 
antigenic stimulation when they are only 30 days old and that the presence or absence of 
maternal antibodies had no bearing on the outcome of a rabies challenge. 
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Materials and method 
FOXES 
The animal model used in this study was the silver fox, which belongs to the same species as the 
‘wild’ red fox, (Vulpes vulpes). All silver fox cubs used were born in the experimental farm of our 
laboratory. Males (17) 1– 4years old and females (40) 2–9 years old, were purchased at least 1 
month before the beginning of the reproductive activity of the vixens from the Norwegian Fur 
Breeder’s Association (Oslo, Norway). On arrival, all were treated with anthelmintics (Droncit®, 
Bayer Pharma, France and Ivomec®, Merial SAS, France) and were vaccinated against canine 
distemper, viral hepatitis, parvovirus infection, infectious tracheobronchitis and leptospirosis 
with Canigen® CHPPi/L (Virbac, France). They were kept in individual cages, fed daily with a 
commercial dry food for adult dogs and water was provided ad libitum. All animals were 
observed daily. 
Vixen health parameters and mating were conducted at our experimental farm. Vixen sexual 
cycles were monitored using both vaginal resistivity and keratinisation of epithelial cells in 
vaginal smears. Once a vixen was determined as receptive, a male was co-housed with it for 1 
day. After this, detection of spermatozoa was performed by examination of vaginal smears to 
assess the covering. In this way it was possible to determine precisely the beginning of the 
gestation period and the estimated parturition time (the mean gestation period being 52 days). 
Covered vixens were then transferred to maternity cages and pregnancy was verified 30 days 
after mating by echography or trans-abdominal palpation. 
When cubs of the litter were 8–9 weeks old, the dam was removed and the cubs were re-caged 
usually in pairs. They were fed daily with commercial dry food for young dogs with drinking 
water ad libitum. According to their size (and usually when 3–4 months old), young foxes were 
placed in individual cages. At this time they were also treated with anthelmintics (Droncit® and 
Ivomec®) and vaccinated with Canigen® CHPPi/L (two injections, 4 weeks apart). 
RABIES VACCINE 
VR-G (or VVTGgRAB oral vaccine bait (Raboral®, Merial SA, France)) is a recombinant vaccinia 
virus (strain Copenhagen, thermosensitive ts 26) expressing the immunising glycoprotein of the 
ERA strain of rabies virus [4]. It has been tested in foxes for safety and efficacy [5,7,20]. 
All vaccine-doses were of the same batch (80U342), stored at + 4 °C until use. Stability of the 
titre of the vaccine was verified by titration on the day of arrival, before the beginning of the 
experiment and after each set of administrations. The titre of VR-G virus was expressed in 
median cell culture infectious dose per dose (CCID50/dose). Titrations were done on VERO cells 
(ATCC No. CCL81) in 96-well microtitre plates, 100 µl of a 2 × 105 cell/ml suspension/well. 
Serial (10-fold) dilutions of the virus were made and six 100-µl replicates of each dilution were 
distributed. After 120 h incubation at 37 °C and 5% CO2 the cytopathic effect of the virus was 
observed with an inverted microscope. Reading was qualitative and a well was considered 
positive as soon as at least one lytic plaque was observed. The virus titre was calculated by the 
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neoprobit graphic method [21]. During the experiment the titre of the VR-G varied between 
108.03 and 108.44 CCID50/dose. 
VACCINATION 
To eliminate variation in the absorbed volume of vaccine, VR-G was administered by direct 
instillation into the oral cavity with a needleness syringe on manually restrained alert animals. 
For both adult and young foxes the instilled volume corresponded to one average dose of VR-G 
vaccine (i.e. 2.7 ml for the batch used in this experiment). 
Pregnant vixens were randomly divided into two groups. Group A had been vaccinated at 30 
days of pregnancy and group B were unvaccinated. From both groups, litters were divided in 
three further groups, E, F, G born to vaccinated and H, J, K born to unvaccinated vixens 
respectively. Cubs of groups E and H were vaccinated when 30 days old and those of groups F 
and J were vaccinated when 90 days old. Fox cubs of groups G and K were not vaccinated. 
BLOOD SAMPLING 
Bleeding was by jugular venepuncture without anaesthesia. All vixens were bled before mating 
and again 30 days after parturition. All cubs were first bled at 30 days of age and thereafter at 2-
week intervals until 5 months of age and again before euthanasia. Serum was tested for rabies 
neutralising antibodies by a modified version of the rapid fluorescent focus inhibition test 
(RFFIT) on microplate [22,23]. The titres obtained were expressed in International Units 
(IU)/ml by comparison with the second WHO standard for Rabies Immunoglobulin (activity of 
30 IU per ampoule). The 0.5 IU/ml conventional level defined in humans as indicative of 
protection against rabies [24] was used as the positive threshold, as it is currently used in rabies 
epidemiological surveys of wildlife. 
CHALLENGE 
The challenge virus was first isolated from sub-maxillary salivary glands of naturally infected 
rabid foxes in 1986 [25]. The batch (GS-7) was then passaged three times in individual foxes 
[26]. A fourth passage was made in six foxes and their pooled sub-maxillary salivary glands 
constituted the GS-9 batch. Titre was determined by intracerebral inoculation of mice. 
All young foxes were challenged when five months old. As cub birth times were spread over 1.5 
months, they were divided into seven groups on the basis of age. In order to challenge the seven 
groups with the same virus suspension, one ampoule of GS-9 was thawed and diluted to give a 
final titre of 103 median mouse intracerebral lethal doses/ml (MICLD50/ml). Aliquots of the 
diluted virus were then stored at −80°C until use and one aliquot was then thawed before each 
set of inoculations. Immediately after each challenge, the virus suspension was back-titrated 
intracerebrally in mice. These measured titres ranged between 102.25 and 102.85 MICLD50/ml. Cub 
challenge was performed by intra- muscular inoculation of 1 ml of virus suspension into the left 
temporal muscle. Previous experiments had shown that a dose of 103 MICLD50 induced a 
mortality time of 18–20 days in unvaccinated foxes [26,27]. As it was impossible to add a control 
litter during every challenge session, the expected mortality delay of controls was arbitrarily 
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fixed to 20 days. The classical observation period for post vaccination challenge is 45 days after 
the death of the last dying control. This allowed the determination of the minimal observation 
period of surviving foxes to 20 + 45 days post challenge. 
Brain material and sub-maxillary salivary glands of all young foxes dying of rabies or euthanased 
at the end of the observation period were examined for the presence of rabies antigen by direct 
immunofluorescence [28] and cell culture test [29]. For ethical reasons, it was decided to 
euthanase rabid animals when paralysed. 
STATISTICAL ANALYSIS 
Statistical analyses were performed on the log10 of the number of IU/ml. Differences between 
groups in the neutralising antibody titre were analysed by using analysis of variance and 
Student’s t-test for unpaired data at a 95% confidence level. 
 
Fig. 1. Relationship between rabies neutralising antibody titres of the vaccinated vixens and titres of their 
30-day-old cubs. (… threshold of positivity: 0.5 IU/ml). 
Results 
FOX CUBS 
Births occurred from the end of March to the beginning of May. Twenty one litters with 97 cubs 
alive at 30 days (whelped by vixens aged from 2 to 6 years) were obtained. The number of cubs 
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per litter ranged from one to seven, with an average of 4.5 (S.D.=1.88). All animals remained in 
good health during the experiment (before challenge) except four cubs that were euthanased 
because of inter-current bacterial infections. 
PASSIVE IMMUNITY OF FOX CUBS 
Fifty two days after oral instillation of the VR-G vaccine (i.e. 30 days after whelping), the 
neutralising antibody titres of the 12 vaccinated females (group A) ranged between 7.31 
(log=0.86) and 32.86 IU/ml (log=1.52). None of the nine unvaccinated vixens (group B) had 
neutralising antibody and none of their cubs (groups H, J and K, n = 43) had antibody to rabies 
virus at 30 days of age. The transferred neutralising antibody titres of the 30-day-old cubs born 
from the 12 vaccinated vixens (groups E, F and G, n=54) ranged from 0.1 (log=−1.0) to 2.59 
IU/ml (log=0.41). A very significant difference between the neutralising antibody titres of these 
cubs and those of cubs born from unvaccinated vixens was shown (P=10−15). The levels of 
neutralising antibodies detected in the 30-day-old cubs were very significantly lower than those 
detected in maternal sera 52 days after vaccination of the vixens (P=9×10−10). Furthermore 
there was no correlation between the neutralising antibody titres of the 12 vaccinated vixens 
and the transferred neutralising antibody titres of their respective 30-day-old cubs (groups E, F 
and G, n=54, r=−0.28) (Fig. 1). 
Fig. 2 shows the frequency distribution of neutralising antibody titres of cubs born to vixens of 
group A measured at 30 days of age. The graph clearly shows three different groups: among the 
54 cubs of vaccinated mothers, 14 had no detectable neutralising antibody, 32 had neutralising 
antibody levels around the 0.5 IU/ml (log=−0.3) cut-off value and eight had higher neutralising 
antibody titres, ranging from 1.58 to 2.59 IU/ml (log=0.2–0.41). 
The mean neutralising antibody titre of each 30 days litter is shown in Fig. 3. A significant 
difference between litters of vaccinated vixens (E1, E2, E4, F1, F3, F4, G1, G3 and G4) 
(F8/40=15.45, P<10−3) was observed. Litters E3, F2 and G2 that had only one or two cubs were 
not included in this statistical analysis. Moreover, we observed that some litters showed 
heterogeneous antibody titres (for example litters F4, G4) whereas some others had 
homogenous antibody titres (for example litters F1, G1). 
Fig. 4(a) demonstrates the kinetics of maternally derived antibodies decline in litters of 
vaccinated vixens and subsequent rise after vaccinated at 90 days (group F). The decline was 
related to the antibody level present at 30 days of age and was similar for all litters. Similar 
results were obtained with unvaccinated fox cubs born to vaccinated vixens (group G, data not 
shown). Duration of maternal antibodies in litter F1 (the highest mean neutralising titre at 30 
days) was the longest, but 
Published in : Vaccine (2001), vol. 19, n°32, pp. 4805–4815 
DOI: 10.1016/s0264-410x(01)00211-0 





Fig. 2. Frequency distribution of rabies neutralising antibody titres of cubs born to vaccinated 
vixens. 
 
Fig. 3. Mean of the rabies neutralising antibody titres of the 30-day-old litters. Litters E, F and G born to 
vaccinated vixens; litters H, J and K born to non-vaccinated vixens. 
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Fig. 4. Kinetics of serological response of fox cubs vaccinated at 90 days born to vaccinated (a) or non-
vaccinated (b) vixens. 
had disappeared by 75 days. None of the litters with a mean titre close to 0.5 IU/ml at 30 days 
had neutralising activity at 45 days (i.e. litter F2 Fig. 4a) and litters G3 and G4 (data not shown)) 
or 60 days after whelping (i.e. litter F4 Fig. 4a) and litter G1 (data not shown)). Fig. 5 shows that 
15 days after vaccination, all cubs of group E (i.e. born to vaccinated vixens and vaccinated at 30 
days of age) had higher rabies neutralising antibody titres. However, there was no correlation 
between the levels of maternally derived antibodies of these cubs at 30 days of age (which were 
similar at the time of the vaccination) and those obtained for these same cubs 15 days after their 
vaccination (Fig. 5, n=17, r=−0.02). 
Fig. 6 shows the kinetics of serological response of cubs born to vaccinated vixens (group E, Fig. 
6a) or to non-vaccinated vixens (group H, Fig. 6b) and vaccinated at 30 days of age. Fifteen days 
after oral administration of the vaccine (i.e. at 45 days of age), rabies antibody level means were 
all increased in all litters (mean=23.55 IU/ml (log=1.34), S.D.=9.33 for Fig. 6a; mean=33.98 
(log=1.51), 
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Fig. 5. Rabies neutralising antibody titres of fox cubs born to vaccinated vixens: relationship between cubs 
pre (i.e. at 30 days of age) and post (i.e. at 45 days of age) vaccination titres. (cubs from litters: + E1, .._ E2, 
• E3, D E4), (… threshold of positivity: 0.5 IU/ml). 
S.D.=13.31 for Fig. 6b). After this, the antibody means slightly decreased until 90 days of age 
(mean= 9.45 IU/ml (log=0.95), S.D.=3.58 for Fig. 6a; mean=10.89 IU/ml (log= 1.02), S.D.=3.28 
for Fig. 6b) and then remained stable until the young foxes were at least 5 months of age 
(mean= 6.55 IU/ml (log=0.77), S.D.=2.86 for Fig. 6a; mean=5.79 IU/ml (log=0.75), S.D.=1.39 
for Fig. 6b), which corresponded to the time of challenge. Comparison of serological results of 
cubs either born to vaccinated vixens (group E, Fig. 6a) or born to non- vaccinated vixens (group 
H, Fig. 6b) shows that 15 days after oral administration (i.e. at 45 days of age), antibody titre 
means were not significantly different (F7/30=2.23, P=0.06). This similarity of antibody titre 
means (0.059<P<0.451) in litters born to vaccinated vixens (group E, Fig. 6a) or to 
unvaccinated vixens (group H, Fig. 6b) was also seen throughout the study (i.e. at 60, 75, 90, 
105, 120 and 150 days of age). 
Fig. 4 shows similar results, with cubs born to vaccinated vixens (group F, Fig. 4a) or to non-
vaccinated vixens (group J, Fig. 4b) and vaccinated at 90 days of age. Rabies antibody kinetics 
were similar to those described above, i.e. increased of levels 15 days after vaccination 
(mean=34.85 IU/ml (log=1.53), S.D.=5.65 for Fig. 4a; mean=36.93 IU/ml (log= 1.54), 
S.D.=17.87 for Fig. 4b) followed by a slight decrease then stability until at least 5 months of age 
(mean=11.5 IU/ml (log=1.03), S.D.=4.28 for Fig. 4a; mean=10.97 IU/ml (log=1.04), S.D.=0.87 
for Fig. 4b). As previously observed for cubs vaccinated at 30 days of age, neutralising antibody 
mean titres of cubs vaccinated at 90 days were similar not only at 15 days after oral 
administration of the vaccine (i.e. at 105 days of age) (F6/24=0.74, P=0.62) but also thereafter 
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(i.e. at 120, 135 and 150 days of age) with no significant difference (0.063<P<0.897) between 
litters born to vaccinated vixens (group F, Fig. 4a) or to unvaccinated vixens (group J, Fig. 4b). 
Comparison of results presented in Figs. 6 and 4 shows that 15 days after vaccination and until 
time of the challenge, neutralising antibody titre means of cubs born to vaccinated or 
unvaccinated vixens and vacci- nated at 30 days (groups E and H) or at 90 days (groups F and J) 
did not significantly differ (0.144<P<0.935). 
 
Fig. 6. Kinetics of serological response of fox cubs vaccinated at 30 days born to vaccinated (a) or non-
vaccinated (b) vixens. 
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RESISTANCE TO CHALLENGE 
Whatever the vaccinal status of the vixens, all vaccinated young foxes (n=65) resisted a rabies 
challenge and all but one unvaccinated young foxes (n=28) died of rabies (Table 1). The mean 
period between challenge and death was 16.5 days (from 13 to 20 days). The clinical phase 
lasted less than 2 days. Rabies was confirmed positive by laboratory tests in non-vaccinated 
foxes and negative on vaccinated animals and the surviving unvaccinated cub at the end of the 
observation period. 
Discussion 
Previous findings have shown that the key to successful rabies oral vaccination in spring is to 
give cubs access to vaccine baits [13,14]. Several methods to improve vaccination coverage of 
cubs have been tested [15,16]. However, few data concerning the ability of cubs to produce 
rabies antibodies in response to SADB19 oral rabies vaccine [30,31] or to VR-G vaccine [32] have 
been reported. Furthermore, it is well known that even if newborn animals are 
immunocompetent at birth, an additional maturation of the immune response will occur during 
the neonatal period. In domestic carnivore species, transfer of maternal antibodies can protect 
neonates against various infections; the presence of blocking levels of those maternal antibodies 
may however be an obstacle to successful later vaccination (reviewed in [18,19]). In the red fox, 
this interference phenomenon has already been suggested [16,32] but reported in only one 
study that used SADB19 oral vaccine [31]. This led us to conduct an experimental trial to assess 
the duration of passive immunity acquired by cubs born to VR-G orally vaccinated vixens and to 
follow the development of immune competency of cubs in order to assess interference between 
passive and active immunity in cubs. 
MATERNAL IMMUNITY 
Few data on rabies maternal antibody transfer have been published. One study [33] of 
parenterally vaccinated (subcutaneous or intramuscular routes) dogs showed that rabies 
neutralising antibodies could not be detected in any puppies born to rabies vaccinated dams 
prior to their vaccination. However, two other studies [34,35] demonstrated that rabies 
neutralising antibodies can be transferred from dams to their pups. According to Winters  et al. 
[34], in dogs transfer of rabies maternal antibodies is partly transplacental but mainly through 
the colostrum. The first studies showing that major transfer of maternal antibodies occurs 
during ingestion of colostrum by new-born pups were de- scribed for canine distemper virus 
[36,37]. This was also reported by Pollock  et al. [38] in a study of maternally derived antibodies 
to canine parvovirus. In this latter study, it was also demonstrated that the amount of maternal 
antibodies that pups receive is proportional to the titre of the dam. 
Our study shows that neutralising antibodies to rabies virus can be transferred to their cubs by 
vixens orally vaccinated with VR-G during pregnancy. Neutralising antibody mean titres in sera 
of these cubs were significantly lower than the titres of maternal sera. However, contrary to the 
studies in dogs [38] and in foxes [31], we observed no correlation between the amount of 
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maternal antibodies of cubs and the titre of their respective mothers. If in foxes, as in dogs, 
maternally derived antibodies are transferred mainly through the colostrum, the absence of 
correlation might be related to poor mother care of some vixens, particularly first time or 
otherwise stressed vixens. 
We also observed that maternal antibody titres were variable both between litters and between 
cubs of a litter. This finding may be due to differences in colostral absorption, as described in 
other multiparous species (reviewed in [19]). Moreover, 14 of the 54 observed cubs belonging 
to the same or different litters (i.e. cubs of litter G2 and some cubs of litters E1, E3, F3 and G4), 
had no detectable neutralising activity in their sera. As serum samples were not collected until 
cubs were 30 days old, it is possible that these cubs may have had low levels of maternal 
antibodies, which had disappeared in under 30 days. 
The period of 30 days before cub bleeding was designed to ensure cub survival, since previous 
unpublished observations in our experimental station had shown that some vixens stressed 
within the first 30 days of parturition cannibalised their cubs or developed poor mothering 
behaviour. Moreover, there appeared to be no relationship between litter size and neutralising 
antibody titres of cubs, but as some vixens killed and cannibalised some of their cubs during the 
first days after birth, absence of a relationship could not be proven. Although it was shown that 
maternally derived antibody titres in cubs declined regularly with time (and disappeared 45–75 
days after birth), we did not investigate their ability to protect against challenge. 
IMMUNE-COMPETENCE OF FOX CUBS 
Reports have shown that when 4–5-week-old pups born to non-immunised dams were 
intramuscularly vaccinated with Flury low egg passage (LEP) rabies vaccine, they are capable of 
producing rabies antibodies, but 10–16-week-old pups responded much better, which suggests 
that the immune response in older dogs is due to a maturation of their immune systems [35,39]. 
Our results showed that 1-month-old fox cubs born to non-vaccinated vixens can respond to VR-
G oral vaccination by the production of specific rabies neutralising antibodies. When the 
neutralising antibody mean titres of these cubs were compared with those of older (90 days) 
cubs, no difference in neutralising titres was observed. This result suggests that in foxes there is 
no additional maturation of the immune system after 30 days of age. The capacity of 30-day-old 
fox cubs to respond to VR-G oral vaccination may even exist earlier, but this possibility was not 
examined in this study in order to ensure cubs survival. 
INTERFERENCE BETWEEN MATERNAL AND ACTIVE IMMUNITY 
According to Aghomo  et al. [35] puppies born to naive bitches intramuscularly vaccinated with 
an attenuated Flury-LEP live virus vaccine presented rabies antibody titres significantly higher 
than those of puppies born to vaccinated bitches. Bernardi  et al. [40] also demonstrated, in 
hamsters born to dams intraperitoneally vaccinated with a rabies inactivated PV virus vaccine 
that the presence of maternal antibodies, even when those antibodies were present at titres 
insufficient to protect against infection, inhibited the formation of an immune response in 
offspring. 
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Our results contrast with these previous reports and also with those of Müller  et al. [31] (in 
which results were obtained in foxes after use of oral live modified vaccine SADB19), since for 
all cubs vaccinated at 30 days we observed no significant difference in the magnitude of 
antibody response between the group of cubs born to vaccinated vixens (group E) and that born 
to unvaccinated vixens (group H). Moreover, whatever the age of vaccination (i.e. 30 or 90 days) 
and the immune status of the vixens, we also observed no significant difference in the magnitude 
of the antibody responses. These data demonstrated the absence of interference between 
passive immunity of maternal origin and active immunity conferred by VR-G oral vaccination. 
Since we performed vaccination with a recombinant vaccine, the type of vaccine might be the 
cause of this discrepancy. However, Seghaier et al. [41] showed that puppies born to dams 
subcutaneously vaccinated with an inactivated rabies vaccine (CVS strain) responded to 
vaccination with no significant interference between maternal and active immunity. Moreover, 
intranasal vaccination with a modified live canine parvovirus vaccine stimulated a good 
antibody response in pups with maternally derived antibodies and vaccinated in the first weeks 
of life [42]. 
RESISTANCE TO CHALLENGE 
Our results, show that all vaccinated cubs challenged at 5 months of age resisted an 
intramuscular challenge with fox street rabies virus, whether or not the vixens have been orally 
vaccinated with VR-G during pregnancy. This demonstrated the absence of interference between 
passive immunity and protection conferred by oral vaccination with VR-G. Survival from a 
severe challenge of a control cub was unexpected, but this phenomenon has already been 
observed in other similar trials [43,44]. 
Our data demonstrated the very early ability of fox cubs to respond to oral vaccination with VR-
G, their ability to resist a severe rabies challenge (killing nine of ten control cubs) and the 
absence of interference between passive antibody of maternal origin and response to oral 
vaccination. Therefore, fox cubs immunisation against rabies with VR-G per os is possible 
whatever the immune status of their mothers. Hence, oral vaccination of fox cubs at den 
entrances with VR-G may protect them. We are presently conducting a similar experiment with 
SAG2 oral vaccine. Trials in which the protective effect of maternally derived antibodies would 
also be determined. 
In other respects, the fact that foxes can respond to antigenic stimulation when they are only 30 
days old, whatever the immune status of the vixen, should be taken in account when interpreting 
the serological results of epidemiological studies. In such studies, the red fox is used as a sentinel 
for the presence of different antigens or diseases in an area because of its opportunistic 
behaviour. This kind of study allows spatial and temporal interpretation. The temporal aspect 
should now consider that at 1 month of age fox cubs may have antibody from either passive 
immunity or from active immunisation. 
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